News

News Subscription

Oct 12. 2020
Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020
Read more
Download
Sep 29. 2020
Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain cancer
Read more
Download
Sep 28. 2020
Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
Read more
Download
Sep 22. 2020
Basilea reports data from poster presentations at ESMO Virtual Congress 2020
Read more
Download
Aug 11. 2020
Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19
Read more
Download
Aug 07. 2020
Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in China
Read more
Download
Jul 28. 2020
Basilea announces completion of its transaction involving a partial repurchase of its existing bond and the issuance of a new bond
Read more Download
Jul 28. 2020
Basilea announces data presentations at ESMO Virtual Congress 2020
Read more
Download
Jul 21. 2020
Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance of tendered Bonds in an aggregated principal amount of approximately CHF 47 million
Read more Download
Jul 20. 2020
Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with derazantinib in bile duct cancer (iCCA)
Read more
Download